公开(公告)号：KR1020120058688A

公开(公告)日：2012-06-08

申请号：KR1020100116411

申请日：2010-11-22

Applicant: (주)아모레퍼시픽

Inventor： 김형준 ,  오택진 ,  이명렬 ,  이종석 ,  박창훈 ,  김한곤 ,  이태룡 ,  노민수 ,  신동욱

IPC: A61K8/37 ,  A61K8/368 ,  A61K8/36 ,  A61K8/49 ,  A61K8/89 ,  A61Q17/04 ,  A61K31/41 ,  A61K31/192 ,  A61K31/215 ,  A61K31/60

CPC classification number: A61K8/37 ,  A61K8/36 ,  A61K8/368 ,  A61K8/4966 ,  A61K8/89 ,  A61K31/192 ,  A61K31/215 ,  A61K31/41 ,  A61K31/60 ,  A61Q17/04

Abstract: PURPOSE: A composition containing cinnamic acid derivatives, methoxy phenyl acrylate derivatives, and beta,beta-diphenylacrylate derivatives is provided to improve photo stability. CONSTITUTION: A composition for sun screening contains cinnamic acid derivatives, methoxy phenyl acrylate derivatives, and beta-beta-diphenyl acrylate derivatives as an active ingredient. The methoxy phenyl acrylate derivative is ethyl hexyl methoxy crylene. The beta-beta-diphenyl acrylate derivative includes octocrylene, etocrylene, or both. The composition further contains triazine derivatives, salicylic acid derivatives, and benzalmalonate derivatives.

Abstract translation: 目的：提供含有肉桂酸衍生物，甲氧基苯基丙烯酸酯衍生物和β，β-二苯基丙烯酸酯衍生物的组合物以改善光稳定性。 构成：防晒组合物含有肉桂酸衍生物，甲氧基苯基丙烯酸酯衍生物和作为活性成分的β-β-二苯基丙烯酸酯衍生物。 甲氧基苯基丙烯酸酯衍生物是乙基己基甲氧基二烯丙基。 β-β-二苯基丙烯酸酯衍生物包括辛烯丙烯，乙酰亚甲基或二者。 组合物还含有三嗪衍生物，水杨酸衍生物和亚苄基丙二酸酯衍生物。

公开(公告)号：KR1020120049634A

公开(公告)日：2012-05-17

申请号：KR1020100110992

申请日：2010-11-09

Applicant: (주)아모레퍼시픽

Inventor： 김형준 ,  이명렬 ,  오택진 ,  김광미 ,  이종석 ,  박창훈 ,  김한곤 ,  노민수 ,  신동욱

IPC: G01N33/15 ,  G01N33/483

Abstract: PURPOSE: A method for evaluating efficiency of UV protector is provided to measure cell apoptosis rate and to accurately protect UV ray. CONSTITUTION: A method for evaluating efficiency of UV protector comprises: a step of applying an UV protector onto UV permeable material; a step of irradiating UV onto the upper portion of the UV permeable material; and a step of measuring cell death of skin cells. The UV permeable material is a quartz plate or band pass filter. The skin cells include keratinocytes, fibroblasts, or melanocytes. The cell death includes apoptosis and necrosis.

Abstract translation: 目的：提供一种评估紫外线保护剂效率的方法，以测量细胞凋亡率并准确保护紫外线。 构成：用于评价UV保护剂效率的方法包括：将UV保护剂涂布在UV透过性材料上的步骤; 将UV照射到UV可渗透材料的上部的步骤; 以及测量皮肤细胞的细胞死亡的步骤。 UV透光材料是石英板或带通滤光片。 皮肤细胞包括角质形成细胞，成纤维细胞或黑素细胞。 细胞死亡包括凋亡和坏死。

公开(公告)号：KR101114006B1

公开(公告)日：2012-02-21

申请号：KR1020080052041

申请日：2008-06-03

Applicant: (주)아모레퍼시픽

Inventor： 이상민 ,  송민정 ,  신동욱 ,  노민수 ,  김한곤

IPC: A61K8/97 ,  A61Q19/00

Abstract: 본 발명은 피부 미용 및 성형용 조성물에 관한 것으로, 보다 상세하게는 백화사설초 추출물을 유효성분으로 함유하여 사람 중간엽줄기세포를 지방세포로 분화하는 것을 촉진시킴으로써 지방세포를 생성하여 피부의 볼륨과 탄력을 부여하는 미용 또는 성형 조성물에 관한 것이다.
백화사설초 * 중간엽 줄기세포 분화 * 지방세포생성

公开(公告)号：KR1020110116370A

公开(公告)日：2011-10-26

申请号：KR1020100035746

申请日：2010-04-19

Applicant: (주)아모레퍼시픽

Inventor： 김형준 ,  이명렬 ,  최현 ,  김광미 ,  노민수 ,  김한곤

IPC: A61K36/28 ,  A61K8/97 ,  A61Q19/00

CPC classification number: A61K36/28 ,  A61K8/97 ,  A61Q19/005 ,  A61Q19/007

Abstract: 본 발명은 블루메아 발사미페라 추출물을 유효 성분으로 포함하는 피부 가려움 완화 및 억제, 피부 보습, 피부 염증 완화 및 억제, 피부 면역성 증가, 피부 과민 반응 개선 또는 아토피 피부 개선 및 치료용 조성물을 개시한다.

公开(公告)号：KR100964433B1

公开(公告)日：2010-06-16

申请号：KR1020080110377

申请日：2008-11-07

Applicant: (주)아모레퍼시픽

Inventor： 노민수 ,  여현주 ,  박선미 ,  신동욱 ,  이형호 ,  김한곤

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/158

Abstract: 본 발명은 피부 기능 향상 물질을 스크리닝(screening)하는 방법으로서, (a) 후보 물질을 피부 세포에 처리하는 단계; (b) MAP17(Membrane-Associated Protein 17kD) 유전자의 상대적 발현량 변화를 검출하는 단계; 및 (c) 상기 유전자의 발현량 변화를 유도하는 후보 물질을 피부 기능 향상 물질로 선택하는 단계를 포함한다.
즉, 본 발명은 MAP17(Membrane-Associated Protein 17kD) 유전자를 표지인자로 하여 MAP17 유전자의 발현량 변화를 통해 피부 기능 향상 물질을 검색하는 신규한 스크리닝 방법으로서, 이를 통해 피부 장벽 기능 향상, 피부 보습 유지, 피부 노화 방지 또는 피부 트러블 완화에 유용한 피부 기능 향상 물질을 효율적으로 스크리닝할 수 있다.
MAP17(Membrane-Associated Protein 17kD), 스크리닝

公开(公告)号：KR1020100025045A

公开(公告)日：2010-03-09

申请号：KR1020080083645

申请日：2008-08-27

Applicant: (주)아모레퍼시픽

Inventor： 신동욱 ,  이상민 ,  송민정 ,  박선미 ,  노민수 ,  김한곤

IPC: A61K31/353 ,  A61P3/10

Abstract: PURPOSE: A medicinal composition for preventing or treating diabetes and plastic surgery is provided to promote adipocyte differentiation and to enhance volume and elasticity of skin. CONSTITUTION: A medicinal composition for promoting differentiation of adipocytes contains (-)catechin, (-)epicatechin gallate, or (-)gallocatechin as an active ingredient. Adipocyte is human bone marrow mesenchymal stem cell. The (-)catechin, (-)epicatechin gallate, or (-)gallocatechin is isolated from green tea. A medicinal composition for treating and preventing type II diabetes and diabetes complication contains the (-)catechin, (-)epicatechin gallate, or (-)gallocatechin.

Abstract translation: 目的：提供用于预防或治疗糖尿病和整形手术的药物组合物，以促进脂肪细胞分化并增强皮肤的体积和弹性。 构成：用于促进脂肪细胞分化的药用组合物含有（ - ）儿茶素，（ - ）表儿茶素没食子酸酯或（ - ）儿茶素素作为活性成分。 脂肪细胞是人骨髓间充质干细胞。 （ - ）儿茶素，（ - ）表儿茶素没食子酸酯或（ - ）儿茶素可与绿茶分离。 用于治疗和预防II型糖尿病和糖尿病并发症的药物组合物含有（ - ）儿茶素，（ - ）表儿茶素没食子酸酯或（ - ）儿茶素。

公开(公告)号：KR1020100000392A

公开(公告)日：2010-01-06

申请号：KR1020080059873

申请日：2008-06-24

Applicant: (주)아모레퍼시픽

Inventor： 신동욱 ,  이상민 ,  박준성 ,  나용주 ,  박혜윤 ,  김덕희 ,  노민수 ,  김한곤

IPC: A61K8/49 ,  A61Q19/00

CPC classification number: A61K8/498 ,  A61K31/352 ,  A61Q19/00

Abstract: PURPOSE: A method and composition for promoting skin regeneration using icariside II is provided to promote proliferation of transient amplifying cells of epidermis base and promote skin regeneration. CONSTITUTION: An icariside II of chemical formula 1 promotes proliferation of skin cells in skin cells. The skin cell is transient amplifying cells(TA cells). A composition for promoting skin regeneration contains the icariside II as an active ingredient. The content of the active ingredient is 0.001-10 weight% based on total weight. The composition regenerates epidermis by promoting proliferation of the TA cells. The composition increases the number of TA cells which express CD71 protein (Cluster of Differentiation 71 Protein) and α6 integrin. The composition increases the expression of CD200(Cluster of Differentiation 200).

Abstract translation: 目的：提供使用艾司替丁II促进皮肤再生的方法和组合物，以促进表皮碱基瞬时扩增细胞的增殖并促进皮肤再生。 构成：化学式1的阿奇瑞德II促进皮肤细胞中皮肤细胞的增殖。 皮肤细胞是瞬时扩增细胞（TA细胞）。 用于促进皮肤再生的组合物含有作为活性成分的阿魏酸二酯。 活性成分的含量为0.001-10重量％。 该组合物通过促进TA细胞的增殖而再生表皮。 该组合物增加表达CD71蛋白（分化蛋白簇71）和α6整联蛋白的TA细胞的数量。 该组合物增加CD200（分化群集200）的表达。

公开(公告)号：KR1020090123049A

公开(公告)日：2009-12-02

申请号：KR1020080048930

申请日：2008-05-27

Applicant: (주)아모레퍼시픽 ,  서울대학교산학협력단

Inventor： 안수선 ,  김수정 ,  이은영 ,  노민수 ,  이태룡 ,  문성준 ,  김한곤 ,  은희철 ,  정진호 ,  김은주 ,  최원우

IPC: C12N15/10 ,  C12N15/09 ,  C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/136

Abstract: PURPOSE: A biomarker of which expression is specifically decreased or suppressed in the sensitive skin is provided to quickly diagnose sensitive skin and used for screening a relieving agent. CONSTITUTION: A biomarker for diagnosing sensitive skin contains gene of which expression is decreased or increased in the sensitive skin compared to healthy skin or a protein encoding the gene. A method for screening a relieving agent of sensitivity comprises: a step of conjugating a candidate agent to a protein encoded by a gene of which expression is increased or decreased in the sensitive skin; and a step of confirming the suppression of protein activity.

Abstract translation: 目的：提供敏感皮肤中特异性降低或抑制表达的生物标志物，以快速诊断敏感皮肤并用于筛选缓解剂。 构成：与健康皮肤或编码该基因的蛋白质相比，用于诊断敏感皮肤的生物标志物含有敏感皮肤中表达降低或增加的基因。 用于筛选敏感性缓释剂的方法包括：将候选试剂与由敏感皮肤中表达增加或减少的基因编码的蛋白质缀合的步骤; 以及确认蛋白质活性抑制的步骤。

公开(公告)号：KR1020090119159A

公开(公告)日：2009-11-19

申请号：KR1020080045032

申请日：2008-05-15

Applicant: (주)아모레퍼시픽

Inventor： 신동욱 ,  노민수 ,  이형호 ,  이상민 ,  송민정 ,  김한곤

IPC: A61K31/202 ,  A61P3/04

CPC classification number: A61K31/202 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: PURPOSE: A pharmaceutical composition for suppressing adipocyte differentiation and reducing lipid droplet is provided to prevent or treat obesity or lipoma. CONSTITUTION: A pharmaceutical composition of adipocyte differentiation contains arachidonyl dopamine. The pharmaceutical composition prevents adipose tissue enlargement-related disease. The adipose tissue enlargement-related disease is obesity or lipoma. The differentiation of adipocyte is from mesenchymal stem cell to adipocyte. The mesenchymal stem cell is human bone marrow mesenchymal stem cell. A formulation of oral administration is used in the form of pill, powder, suspension, emulsion, syrup, and granule.

Abstract translation: 目的：提供抑制脂肪细胞分化和降低脂滴的药物组合物，以预防或治疗肥胖或脂肪瘤。 构成：脂肪细胞分化的药物组合物含有花生四烯多巴胺。 该药物组合物防止脂肪组织扩大相关疾病。 脂肪组织增生相关疾病是肥胖或脂肪瘤。 脂肪细胞的分化是从间充质干细胞到脂肪细胞。 间充质干细胞是人骨髓间充质干细胞。 口服给药的制剂以丸剂，粉剂，悬浮液，乳剂，糖浆剂和颗粒剂的形式使用。

公开(公告)号：KR1020090032372A

公开(公告)日：2009-04-01

申请号：KR1020070097553

申请日：2007-09-27

Applicant: 한국화학연구원 ,  (주)아모레퍼시픽

Inventor： 공영대 ,  조희영 ,  전문국 ,  이태호 ,  최길돈 ,  공재양 ,  정대영 ,  황순희 ,  김정주 ,  이창훈 ,  고재영 ,  노민수 ,  한은실 ,  김형준 ,  김혁 ,  윤준원 ,  모주현 ,  김도훈

IPC: C07D277/44 ,  C07D417/04 ,  C07D417/12 ,  A61K31/426

CPC classification number: C07D277/46 ,  C07D417/04 ,  C07D417/12

Abstract: Provided is 2,4,5-trisubstituted-1,3-thiazole derivatives having excellent inhibiting activity about SPC(sphingosylphosphorylcholine) receptor to treat inflammatory diseases caused by activity of the SPC acceptor. A therapeutic agent for treating inflammatory diseases caused by activity of SPC acceptor comprises a 2,4,5-trisubstituted-1,3-thiazole derivative represented by the formula 1 and pharmaceutically allowable salts thereof. A method for preparing the 2,4,5-trisubstituted-1,3-thiazole derivative consists of the following steps of: reacting methyl cyanocarbonimidodithionate represented by the formula 2 to 2-haloacetophenone in order to synthesize 4-amino-1,3-thiazol represented by the formula 3; and polymerizing chloridation carboxylic acid to 4-amino group of the 4-amino-1,3-thiazol to synthesize 4-N-acyl-1,3-thiazole represented by the formula 4.

Abstract translation: 提供对SPC（鞘氨基磷酰胆碱）受体具有优异抑制活性的2,4,5-三取代-1,3-噻唑衍生物，用于治疗由SPC受体的活性引起的炎性疾病。 用于治疗由SPC受体的活性引起的炎性疾病的治疗剂包括由式1表示的2,4,5-三取代-1,3-噻唑衍生物及其药学上允许的盐。 制备2,4,5-三取代-1,3-噻唑衍生物的方法包括以下步骤：使由式2表示的氰基羰基亚氨基二硫代乙酸甲酯与2-卤代苯乙酮反应，以合成4-氨基-1,3- 由式3表示的噻唑; 并将氯化羧酸聚合成4-氨基-1,3-噻唑-4-氨基，合成由式4表示的4-N-酰基-1,3-噻唑。